Expedition Therapeutics raises $115.0M Series B (United States, Aug 2026)
Reach the investors backing rounds like this
Backed by General Atlantic, RA Capital +6 more · verified emails and LinkedIn on Datapile
Expedition secures $115 million to tackle COPD inflammation - Longevity.Technology
Expedition Therapeutics is a biotechnology company focused on developing innovative therapies for chronic obstructive pulmonary disease (COPD). The company is notable for its lead therapy, EXPD-101, which targets inflammation in the lungs, aiming to intervene earlier in the disease process rather than just alleviating symptoms. The recent $115 million Series B financing will support the launch of a global Phase 2 clinical trial for this treatment.
Expedition secures $115 million to tackle COPD inflammation Longevity.Technology
| Sep 23, 2026 | Ema | $77.0M | Series B | United States |
| Sep 23, 2026 | Baselayer | $35.0M | Series A | United States |
| Sep 23, 2026 | Hubble Network | $200.0M | Series C | United States |
| Sep 23, 2026 | Topdog | $2.5M | Seed | United States |
21,386 investors back startups in United States
You just read who funded Expedition Therapeutics. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.